- Trial phase
- Phase 2b
- Time to market
- If Phase 3 trials begin in 1H 2027 and run successfully, a BLA submission and potential FDA approval would likely be several years away, possibly in the 2029-2030 timeframe. The company has stated its $1.1 billion cash position funds operations through a BLA filing.
- Why 6/10
- The next hard, dated catalyst is the EVERLAST-A 52-week durability data expected in December 2026 (about one month away). This is a Phase 2a long-term follow-up readout, not a pivotal registration trial, but it is a major value driver for the company. ORKA-001 is the lead asset, though the company also has ORKA-002 in its pipeline, so it is not entirely single-asset. The score reflects a dated binary within 1-6 months on the lead asset at a company with other programs.
The key catalyst to watch is the EVERLAST-A 52-week data expected in December 2026, which will demonstrate whether ORKA-001's skin-clearing responses hold up a full year after just two doses. Strong durability would reinforce the ultra-durable dosing thesis and support the Phase 3 design. Weak durability would challenge the core value proposition. Phase 3 initiation in 1H 2027 and ORKA-002 Phase 2 data in Q1 2027 are secondary catalysts. The $1.1B cash runway removes financing overhang through a BLA filing.
Price Chart
Executive Summary
ORKA-001 is Oruka Therapeutics' lead drug candidate, a half-life extended monoclonal antibody targeting IL-23p19 for moderate-to-severe plaque psoriasis. It has produced highly consistent Phase 2 efficacy data across two trials (EVERLAST-A and EVERLAST-B), achieving 61-63% complete skin clearance (PASI 100) at Week 16 with deepening responses through Week 28 without additional dosing. The company has a $1.1 billion cash position, strong institutional backing, and a unanimous bullish analyst consensus. The next major catalyst is the 52-week durability data from the EVERLAST-A trial expected in December 2026, followed by Phase 3 initiation in the first half of 2027. ORKA-001's ultra-durable profile could enable dosing as infrequently as 1-2 times per year, a potential competitive advantage over current standard-of-care IL-23 inhibitors.
How It Works
ORKA-001 is a lab-engineered antibody (a monoclonal antibody) designed to block a specific inflammatory signal called IL-23p19, which drives the skin inflammation in psoriasis. It is injected under the skin and engineered with an extended half-life, meaning it stays active in the body much longer than existing drugs. The goal is to achieve clear skin with as few as one or two injections per year, compared to every 8-12 weeks for current standard-of-care drugs like Skyrizi or Tremfya.
Trial Status
ORKA-001 has completed two Phase 2 trials in moderate-to-severe plaque psoriasis. The Phase 2a EVERLAST-A trial (84 patients) showed 63% of patients achieving complete skin clearance (PASI 100) at Week 16, deepening to 71% at Week 28 with no additional dosing after Week 4. The Phase 2b EVERLAST-B trial replicated these results, with the 600 mg high-dose group achieving 61% PASI 100 and 86% PASI 90 at Week 16 versus 0% for placebo (p<0.0001). Safety was favorable with no serious adverse events in the high-dose group and no injection site reactions. The company plans to initiate Phase 3 trials in the first half of 2027.
The Two-Sided Case
Upcoming Catalysts
- EVERLAST-A 52-week durability data expected December 2026
- Phase 3 trial initiation expected in first half of 2027
- ORKA-002 (second pipeline drug) Phase 2 Week 16 data expected Q1 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Oruka Therapeutics, Inc. PRESS-RELEASE ORKA ·Originating report